COMMON QUESTIONS / DIRECT ANSWERS
Ask Better Questions About Peptide Evidence
Brief answers drawn from the composed literature, with the regulatory and safety boundaries left intact.
What is tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. It signals the pituitary to increase the body’s own growth-hormone pulses and downstream IGF-1. In the United States, it is an approved prescription medicine for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [2]. That narrow indication should not be rewritten as approval for general weight loss, bodybuilding, or anti-aging.
What does tesamorelin do?
In its best-studied population, tesamorelin reduces visceral fat, the fat surrounding abdominal organs. A pooled analysis also found changes in trunk fat, hepatic fat, and lean mass [1]. The effect depends on continued treatment in the long-term program; visceral fat reaccumulated after discontinuation [5].
How does tesamorelin work?
It activates growth hormone-releasing hormone receptors on pituitary cells. That increases endogenous growth hormone and, downstream, liver production of IGF-1. Those signals promote fat breakdown. A physiology study documented increased overnight growth hormone and IGF-1 [4].
Will tesamorelin help me lose belly fat?
That is an individual treatment question this digest cannot answer. Trials support reduced visceral abdominal fat in adults with HIV-associated lipodystrophy [1][3][6]. They do not establish the same benefit-risk balance for general weight loss or other populations. A clinician would need to address diagnosis, indication, contraindications, and monitoring.
What does retatrutide do?
Retatrutide activates GIP, GLP-1, and glucagon receptors. Phase 2 trials report substantial reductions in body weight, glucose measures, and liver fat in defined study populations [10][11][12]. It remains investigational, so these results are not an approval or a complete long-term safety record [8].
How does retatrutide work?
The GIP and GLP-1 arms influence appetite and glucose-dependent insulin release. The glucagon arm is intended to add energy expenditure and lipid mobilization. Structural research confirms engagement of all three receptors with different relative activity at each [9].
How is retatrutide reconstituted?
This site does not provide reconstitution or administration instructions. Retatrutide is investigational, and the published studies used controlled material under formal protocols [8][11]. Instructions for unverified material would imply an identity, concentration, sterility, and suitability that the evidence cannot establish.
Is retatrutide FDA approved?
No. The composed research record identifies retatrutide as an investigational compound in clinical development, not an approved medicine [8]. Published Phase 2 results do not substitute for completed pivotal trials and regulatory review.
What does BPC-157 do in the body?
Preclinical research links BPC-157 to blood-vessel and repair signaling through VEGFR2, Akt, and endothelial nitric-oxide synthase [16]. Animal studies report gastric protection [17]. What it reliably does in humans is not established because rigorous human efficacy trials are lacking [14].
Is BPC-157 a growth hormone?
No. BPC-157 is a synthetic 15-amino-acid peptide, not growth hormone [14]. Some proposed repair mechanisms may intersect with growth signaling, but that does not change its identity or prove a human therapeutic effect.
Does BPC-157 work immediately?
There is no rigorous human evidence establishing that it works at all for the popular injury and gut claims, much less a reliable time to effect [14]. Community timelines are anecdotal, not clinical evidence, and cannot answer the question.
Does BPC-157 damage the liver?
The available record does not establish human liver injury, but the human dataset is far too small for a confident safety conclusion. A two-person pilot found no measurable change in selected hepatic markers [13]. That is not enough to rule out uncommon or long-term harm.
What is thymosin alpha-1?
Thymosin alpha-1 is a naturally derived immune-signaling peptide; thymalfasin is the sequence-identical synthetic form. It influences dendritic cells, monocytes, and T-cell responses. It is approved in multiple countries but not for US marketing [19].
What is thymosin alpha-1 used for?
It has been studied across chronic viral disease, severe infections, immune suppression, and as an adjunct in oncology. Those uses do not share one level of evidence. The large phase 3 sepsis trial found no mortality benefit [18], while other settings have produced signals that remain more limited [20][21][22].
Is thymosin alpha-1 FDA-approved?
No. It is not approved for marketing in the United States, despite approval and clinical use in other countries [19]. International availability should not be presented as FDA approval.